About
About us
Photocure Technology®
Research & Innovation
History
Management
Board of Directors
Media
Contact us
Bladder Cancer
Bladder Cancer Challenge
Bladder Cancer Patient Journey
Bladder Cancer Treatment
Blue Light Cystoscopy
Products
Products on the Market
Products divested or out-licensed
Partnering
Why Partner with Photocure
Our partners
Careers
Investors
Investment Highlights
Share Information
Largest Shareholders
Financial Calendar
Congresses & Events
Stock Exchange Notices
Reports and Presentations
Analyst Coverage
Corporate Governance
Transparency
News
Home
News
Latest News
Photocure announces results from phase II study in acne with Visonac™
28 May 2010
Expert panel recommends the use of Hexvix®-cystoscopy
21 Apr 2010
Hexvix® receives reimbursement approval in Germany
13 Jan 2010
Photocure received positive response from FDA on the New Drug Application (NDA) for Hexvix® for detection of bladder cancer
31 Dec 2009
FDA Advisory Committee voted favourably to Hexvix® application in USA
18 Dec 2009
Photocure granted patent in Europe and Russia for Visonac™ in the treatment of acne
26 Nov 2009
Presentations held at Photocure ASA's Capital Markets Day
03 Nov 2009
Photocure divests Metvix® to Galderma for EUR 51 million
07 Oct 2009
Hexvix® cystoskopi finner mer kreft og gir mindre tilbakefall
11 Jun 2009
Hexvix® cystoscopy detects more cancer and reduces recurrence
11 Jun 2009
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
